The purpose of the report is to illustrate the state of the market of Blood Processing Devices and Consumables, to present actual information about the volumes of production, exports, imports, consumption and the state of the market, the changes that took place in 2017, and also, to build a forecast for the growth of the industry in the medium term until 2026. [Continue Reading]
Tardive dyskinesia (TD) treatment drugs market is expected to show significant market growth over the forecast period due to increase in incidence of TD, rising number of antipsychotic prescriptions, developing healthcare infrastructure and presence of late stage pipeline molecule. The global TD treatment drugs market is categorized on the basis of drug type such as valbenazine, deutetrabenazine and others (benzodiazepines, botulinum toxin, vitamin E, amantadine, levodopa, reserpine, dopamine-depleting agents and calcium channel blockers etc.). It is observed that the demand for valbenazine and deutetrabenazine is highest in market due to the efficacy and target specificity. Valbenazine and deutetrabenazine were approved in 2017. Furthermore, being the only approved drugs in the market, these drugs will experience significant demand.
Neurocrine Biosciences announced that the recently approved, Ingrezza (valbenazine) achieved $45.8 million net sales in third quarter in 2017. Expected launch of pipeline drug such as SNC-102 (Synchroneuron) would further drive the market growth during forecast period. Currently, North America leads the global TD treatment drugs market due to higher cost of therapeutics, early diagnosis of the disease and increase in prevalence of TD. It is predicted that TD treatment drugs market in Asia Pacific will grow significantly in coming years due to growing number of affected population and emerging healthcare infrastructure.
Leading Players: Neurocrine Biosciences, Inc., Teva Pharmaceutical Industries Ltd’s, Pfizer Inc., Biogen, Novartis AG, Johnson & Johnson Services, Inc., AstraZeneca, GlaxoSmithKline plc., Bayer AG , and Sanofi.
Browse here for full report with Toc: https://www.credenceresearch.com/report/tardive-dyskinesia-td-treatment-drugs-market
Why was the report written?
This report is the result of an extensive survey drawn from Credence Research’s exclusive panel of leading global market industry executives; it provides data and analysis on buyer investment, acquisition, and developments within the global market research. It includes key topics such as global Tardive Dyskinesia (TD) Treatment Drugs buyer expenditure and procurement behaviors and strategies and recognizes the threats and possibilities within the industry, economic outlook trends, and business confidence within global industry executives. Most secondary research reports are based on general industry drivers and do not understand the industry executives’ attitude and changing behaviors, creating a gap in presenting the business outlook of the industry; in an effort to bridge this gap, Credence Research created this primary research-based report by gathering the opinions of multiple stakeholders in the value chain of the global industry. [Continue Reading]
What is the current market landscape and what is changing?
Executives from the global industry anticipate an increase in levels of consolidation, with 55% of respondents projecting an increase in merger and acquisition (M&A) activities in 2017.
The report on the market of Tardive Dyskinesia (TD) Treatment Drugs contains:
Analysis and forecast of Tardive Dyskinesia (TD) Treatment Drugs market dynamics;
Analysis of domestic production, market shares of the main market players;
Analysis of exports and imports;
Analysis of factors, leading the development of the Tardive Dyskinesia (TD) Treatment Drugs market;
Assessment and forecast of Tardive Dyskinesia (TD) Treatment Drugs market development;
Financial and business profiles of the leading companies in theTardive Dyskinesia (TD) Treatment Drugs industry.
– Up to date working Tardive Dyskinesia (TD) Treatment Drugs data by major regions in the world, the forecast of planned capacity additions by 2026
– The annual breakdown of capital expenditure spending on proposed Tardive Dyskinesia (TD) Treatment Drugs for the period 2018 to 2026
– Planned Tardive Dyskinesia (TD) Treatment Drugs additions and capital expenditure spending by key countries and companies across the world
– Planned capital expenditure spending on new Tardive Dyskinesia (TD) Treatment Drugs projects by region, key countries, and companies
– Details of major planned Tardive Dyskinesia (TD) Treatment Drugs projects in the world up to 2026
Browse here for full report with Toc:https://www.credenceresearch.com/report/tardive-dyskinesia-td-treatment-drugs-market
Also you can request us for sample in pdf with more details and graph:https://www.credenceresearch.com/sample-request/58936
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.
Credence Research Inc.
105 N 1st ST #429
Toll Free (US/CANADA): +1-800-361-8290